A quantitative multimodal metabolomic assay for colorectal cancer

Simple item page
dc.contributor.authorFarshidfar, Farshad
dc.contributor.authorKopciuk, Karen A
dc.contributor.authorHilsden, Robert
dc.contributor.authorMcGregor, S. E
dc.contributor.authorMazurak, Vera C
dc.contributor.authorBuie, W. D
dc.contributor.authorMacLean, Anthony
dc.contributor.authorVogel, Hans J
dc.contributor.authorBathe, Oliver F
dc.date.accessioned2018-09-26T12:01:14Z
dc.date.available2018-09-26T12:01:14Z
dc.date.issued2018-01-04
dc.date.updated2018-09-26T12:01:14Z
dc.description.abstractAbstract Background Early diagnosis of colorectal cancer (CRC) simplifies treatment and improves treatment outcomes. We previously described a diagnostic metabolomic biomarker derived from semi-quantitative gas chromatography-mass spectrometry. Our objective was to determine whether a quantitative assay of additional metabolomic features, including parts of the lipidome could enhance diagnostic power; and whether there was an advantage to deriving a combined diagnostic signature with a broader metabolomic representation. Methods The well-characterized Biocrates P150 kit was used to quantify 163 metabolites in patients with CRC (N = 62), adenoma (N = 31), and age- and gender-matched disease-free controls (N = 81). Metabolites included in the analysis included phosphatidylcholines, sphingomyelins, acylcarnitines, and amino acids. Using a training set of 32 CRC and 21 disease-free controls, a multivariate metabolomic orthogonal partial least squares (OPLS) classifier was developed. An independent set of 28 CRC and 20 matched healthy controls was used for validation. Features characterizing 31 colorectal adenomas from their healthy matched controls were also explored, and a multivariate OPLS classifier for colorectal adenoma could be proposed. Results The metabolomic profile that distinguished CRC from controls consisted of 48 metabolites (R2Y = 0.83, Q2Y = 0.75, CV-ANOVA p-value < 0.00001). In this quantitative assay, the coefficient of variance for each metabolite was <10%, and this dramatically enhanced the separation of these groups. Independent validation resulted in AUROC of 0.98 (95% CI, 0.93–1.00) and sensitivity and specificity of 93% and 95%. Similarly, we were able to distinguish adenoma from controls (R2Y = 0.30, Q2Y = 0.20, CV-ANOVA p-value = 0.01; internal AUROC = 0.82 (95% CI, 0.72–0.93)). When combined with the previously generated GC-MS signatures for CRC and adenoma, the candidate biomarker performance improved slightly. Conclusion The diagnostic power for metabolomic tests for colorectal neoplasia can be improved by utilizing a multimodal approach and combining metabolites from diverse chemical classes. In addition, quantification of metabolites enhances separation of disease-specific metabolomic profiles. Our future efforts will be focused on developing a quantitative assay for the metabolites comprising the optimal diagnostic biomarker.
dc.identifier.citationBMC Cancer. 2018 Jan 04;18(1):26
dc.identifier.doihttps://doi.org/10.1186/s12885-017-3923-z
dc.identifier.urihttp://hdl.handle.net/1880/107878
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.titleA quantitative multimodal metabolomic assay for colorectal cancer
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12885_2017_Article_3923.pdf
Size:
1013.88 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications